| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2837273 | Cardiovascular Revascularization Medicine | 2012 | 5 Pages |
Abstract
The addition of ranolazine to maximally tolerated conventional antianginal drug therapy post coronary revascularization was associated with decreases in angina episodes and SLNTG utilization and improvement in CCS angina grades. Ranolazine may provide an effective treatment option for revascularized patients with refractory angina.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Molecular Medicine
Authors
R. Shane Greene, Robert M. Rangel, Krystal L. Edwards, Lisa M. Chastain, Sara D. Brouse, Carlos A. Alvarez, Laura J. Collins, Emmanouil S. Brilakis, Subhash Banerjee,